[{"Assets_0_Q2_USD":32600000.0,"CommonStockSharesOutstanding_0_Q2_shares":38649237.0,"EarningsPerShareBasic_1_Q2_USD":-0.09,"EarningsPerShareBasic_2_Q2_USD":-0.23,"EarningsPerShareDiluted_1_Q2_USD":-0.09,"EarningsPerShareDiluted_2_Q2_USD":-0.23,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-9200000.0,"NetIncomeLoss_1_Q2_USD":-3400000.0,"NetIncomeLoss_2_Q2_USD":-8700000.0,"StockholdersEquity_0_Q2_USD":10800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":38649237.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":38649237.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":38649237.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":38649237.0,"Ticker":"VXRT","CIK":"72444","name":"AVIRAGEN THERAPEUTICS, INC.","OfficialName":"Vaxart Inc Common Stock","form":"10-Q","period":"20171231","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"564888665.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180206"}]